RIVANNA Chosen for MedTech Innovator 2025 Accelerator Program

RIVANNA Selected for Prestigious MedTech Innovator 2025 Accelerator

RIVANNA®, a trailblazer in medical devices focusing on imaging-based solutions, has recently announced a remarkable achievement: the company has been chosen to join the highly esteemed MedTech Innovator 2025 Accelerator Cohort. Out of nearly 1,500 global contenders, RIVANNA stands out as one of only 65 selected startups, highlighting its innovative prowess in the medtech arena.

For those unfamiliar, MedTech Innovator (MTI) is recognized as the world's largest accelerator dedicated to addressing challenges in medical technology. This highly competitive four-month program is designed to furnish participants with exceptional mentorship, strategic guidance, and unparalleled access to a broad network of investors, healthcare providers, and industry experts.

Dr. Will Mauldin, Co-founder and CEO of RIVANNA, expressed his enthusiasm regarding the selection, stating, "Being selected for this year’s MedTech Innovator cohort is an honor and a meaningful endorsement of our commitment to advancing procedural safety." He further explained the significance of their flagship technology, the Accuro® 3S, which is the first AI-enabled ultrasound guidance system specifically tailored for neuraxial anesthesia—a critical advancement that aims to mitigate long-standing challenges in the field.

The Accuro 3S has been meticulously engineered to enhance real-time, image-guided needle placement procedures, particularly for epidurals and spinal blocks. Dr. Mauldin emphasized that this program represents a strategic opportunity for RIVANNA to validate its innovative technology, solidify strategic partnerships within the industry, and expedite its journey toward commercialization.

Throughout the course of the accelerator, companies in the cohort will showcase their innovations at prominent industry events, including the MedTech Conference powered by AdvaMed scheduled from October 5–8 in San Diego, and the MedTech Strategist Innovation Summit set for November 19–21 in the same city. These events not only serve as platforms for networking but also present opportunities to compete for a share of an impressive $800,000 in non-dilutive funding.

About RIVANNA

Founded in 2010 and based in Charlottesville, VA, RIVANNA has quickly emerged as a leader in the development and manufacturing of groundbreaking medical devices. The company's primary mission revolves around creating and commercializing pioneering imaging technologies aimed at elevating global healthcare standards. RIVANNA specializes in offering early and late-stage point-of-care imaging solutions, encompassing spinal needle interventions, fracture detection, and soft tissue diagnostics.

Leveraging advanced 2D/3D ultrasound technology, RIVANNA's innovative platform integrates AI-driven anatomical guidance and diagnostics. This suite of solutions targets critical gaps in healthcare delivery, making a significant impact across various settings including hospitals, ambulatory centers, emergency medical facilities, and military environments. The company boasts robust support from key federal funding bodies, such as the National Institutes of Health (NIH) and the Department of Defense (DoD), alongside contributions from private investors.

About MedTech Innovator

MedTech Innovator stands as a global leader in accelerating the growth of medical device, digital health, and diagnostic enterprises. Their mission is to enhance human health by facilitating the development of companies that are at the forefront of transforming patient care. Since its inception, MTI has attracted nearly 14,000 applicants and has successfully nurtured over 700 startups, collectively raising around $10 billion in follow-on funding and introducing more than 400 products to the market, thereby positively influencing millions of lives across the globe.

For more insights on MedTech Innovator and a detailed overview of RIVANNA's contributions to medical technology, visit their website or follow them on social media.